Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
    3.
    发明授权
    Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 有权
    N-(叔丁氧基羰基)-3-甲基-L-缬氨酰基 - (4R)-4 - ((7-氯-4-甲氧基-1-异喹啉基)氧基)-N - ((1R,2S) -1 - ((环丙基磺酰基)氨基甲酰基)-2-乙烯基环丙基)-L-脯氨酰胺

    公开(公告)号:US08338606B2

    公开(公告)日:2012-12-25

    申请号:US13472720

    申请日:2012-05-16

    IPC分类号: C07D217/22 A61K31/47

    CPC分类号: C07D401/12

    摘要: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

    摘要翻译: 本发明一般涉及N-(叔丁氧基羰基)-3-甲基-L-缬氨酰基 - (4R)-4 - ((7-氯-4-甲氧基-1-异喹啉基)氧基)-N- ((1R,2S)-1 - ((环丙基磺酰基)氨基甲酰基)-2-乙烯基环丙基)-L-脯氨酰胺。 本公开还通常涉及包含一种或多种结晶形式的药物组合物,以及在治疗丙型肝炎病毒(HCV)中使用结晶形式的方法以及获得这种结晶形式的方法。

    Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide
    5.
    发明授权
    Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide 有权
    N-(叔丁氧基羰基)-3-甲基-L-缬氨酰基 - (4R)-4 - ((7-氯-4-甲氧基-1-异喹啉基)氧基)-N-((1R,2S) -1 - ((环丙基磺酰基)氨基甲酰基)-2-乙烯基环丙基)-L-脯氨酰胺

    公开(公告)号:US08202996B2

    公开(公告)日:2012-06-19

    申请号:US12329969

    申请日:2008-12-08

    IPC分类号: C07D217/22 A61K31/47

    CPC分类号: C07D401/12

    摘要: The present disclosure generally relates to crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide. The present disclosure also generally relates to a pharmaceutical composition comprising one or more of the crystalline forms, as well of methods of using the crystalline forms in the treatment of Hepatitis C virus (HCV) and methods for obtaining such crystalline forms.

    摘要翻译: 本发明一般涉及N-(叔丁氧基羰基)-3-甲基-L-缬氨酰基 - (4R)-4 - ((7-氯-4-甲氧基-1-异喹啉基)氧基)-N- ((1R,2S)-1 - ((环丙基磺酰基)氨基甲酰基)-2-乙烯基环丙基)-L-脯氨酰胺。 本公开还通常涉及包含一种或多种结晶形式的药物组合物,以及在治疗丙型肝炎病毒(HCV)中使用结晶形式的方法以及获得这种结晶形式的方法。